The new face of fighting cancer

The battle against cancer has raged for decades and the end game is nearing. Merus’ innovative bispecific antibody therapeutics referred to as Biclonics® are designed to recruit the immune system to kill cancer cells and tip the balance in favor of patients with more effective treatments that have less side effects. Ultimately, it is Merus’ goal to help declare victory for patients with this devastating disease to help them lead normal lives.

Read more

Product Candidates

Human Biclonics®

Biclonics® are designed to possess a format of antibodies that are produced naturally by the immune system, and are designed to retain their favorable attributes including stability, predictability during manufacturing, long half-life and low immunogenicity during treatment of patients.

Read more
UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
– Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of… 
– MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented… 
UTRECHT, The Netherlands, August 7, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
– Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid… 
UTRECHT, The Netherlands, July 5, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage… 
UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage… 
– IND Accepted in April by the U.S. FDA for MCLA-158 – UTRECHT, The… 
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative… 

The new face of fighting cancer

the company's presence in 2018

Upcoming events

Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events.

All events